Cure My Disease

Don't miss your cure!

 Log in / Sign up

Artificial intelligence could help guide liver cancer treatment after surgery

NCT ID NCT07700082

Knowledge-focused Sponsor: Anhui Provincial Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This study developed an artificial intelligence model that analyzes MRI scans and pathology images to predict the risk of liver cancer returning after surgery. Researchers used data from over 500 patients who had their liver cancer surgically removed. The goal is to help doctors decide which patients might benefit from additional treatments after surgery to prevent recurrence.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this AI tool could help doctors identify which liver cancer patients are at high risk of recurrence after surgery and may benefit from additional therapy.
What could go wrong
This is a retrospective observational study, not a clinical trial testing a treatment. The AI model needs prospective validation before it can be used in practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

555 people

The number who actually took part.

Started

Jan 2020

Finished

Jan 2026

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of 555 adult patients with pathologically confirmed hepatocellular carcinoma who underwent curative hepatectomy. All subjects had complete preoperative gadoxetic acid-enhanced MRI, digital pathological whole-slide images, clinical records and long-term follow-up data. Cases were retrospectively collected from three Chinese tertiary hospitals and the public TCGA-LIHC database, excluding patients with incomplete imaging, pathological or follow-up information.

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. patients with pathologically confirmed hepatocellular carcinoma (HCC); 2. patients accepting curative surgical resection (SR) without preoperative adjuvant treatment; 3. MRI were performed two weeks before surgery. Exclusion Criteria: 1. incomplete clinical information; 2. incomplete or suboptimal quality of preoperative MRI imaging data; 3. unavailable or poor-quality pathological whole slide images (WSIs); 4. incomplete follow-up data.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatocellular carcinoma (HCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatocellular carcinoma (HCC)

Contacts and locations

Locations

  • The First Affiliated Hospital of University of Science and Technology of China

    Hefei, Anhui, 230000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.